CAI
Caris Life Sciences Inc
NASDAQ · Biotechnology
$22.00
+0.75 (+3.53%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 418.51M | 1.64B | 1.52B | 1.76B |
| Net Income | -286,153,441 | 316.28M | 306.08M | 281.70M |
| EPS | — | — | — | — |
| Profit Margin | -68.4% | 19.3% | 20.1% | 16.0% |
| Rev Growth | — | +14.2% | +10.8% | -1.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.37B | 1.38B | 1.27B | 1.60B |
| Total Equity | 1.74B | 5.23B | 4.48B | 5.40B |
| D/E Ratio | 0.79 | 0.26 | 0.28 | 0.30 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -261,239,865 | 415.16M | 429.14M | 456.09M |
| Free Cash Flow | — | 185.08M | 215.40M | 287.32M |